The 2024 FDA Diversity Guidance Update: What does it mean for patients, sites, sponsors and CROs
The FDA's June 2024 draft diversity guidance builds on their 2022 draft guidance to make clinical trials even more inclusive by going beyond race and ethnicity to include other demographic characteristics.
This video brings together a panel of experienced clinical research experts to share their perspectives on what this updated FDA Draft Diversity Guidance means for sponsors, sites, CROs and, most importantly, study participants. They’ll discuss what is new to the 2024 guidance, how sponsors, sites and CROs will operationalize it, how this guidance impacts global clinical trials, and more.